AstraZeneca has already manufactured 10 million doses in Argentina and is sending them to Mexico in January

Argentina is already able to apply AstraZeneca coronavirus vaccine, after ANMAT approval, but they still have to pass at least three months so that the first doses are available in Argentina, as announced by the national government: it would be between the end of March and the beginning of April.

In the meantime, the country would have at its disposal the new doses of vacuna rusa Sputnik V that they arrive between January and February. They should come from both the first and second dose.

As of today, there is a stock equivalent to 10 million doses of AstraZeneca vaccine, ready to pack. As Clarín learned, mid-January This volume of the active ingredient of the vaccine will be sent to Mexico for bottling.

This production was carried out in the MAbxience factory in Garín, owned by the Sigman group. There is the base of operations from which AstraZeneca has planned to supply all Latin America with vaccineexcept Brazil.

Anmat vaccine approval could be finalized before the end of the year despite the fact that the phase 3 trial had some methodological setbacks and the AstraZeneca laboratory had to repeat part of the experiment.

The problem arose when a group of volunteers had received two standard doses of the vaccine, with an efficacy of 62.1%. Due to an inconvenience attributed to an accident, another group received a half dose and then a full dose, with which the effectiveness increased to 90%.

Once in Mexico, the Liomont laboratory must validate the batches and demonstrate safety and hygiene in the fragmentation and filling step. Then, AstraZeneca must distribute the vaccines according to the commitments made in Latin America: Argentina bought 22.4 million doses.

The mAbxience laboratory has a production capacity of approximately 25 million monthly doses of the active ingredient. And Mexico has a filling capacity of 23 million doses per month.

The agreement between AstraZeneca and mAbxience was announced in August. From that moment began what is called “technology transfer”, so that the Argentine laboratory is able to manufacture the Oxford vaccine.

After this step, the production itself began, At risk that the phase 3 trials failed to pass international approvals. Until now, Britain and Argentina have already given them the green light and in this way production will continue.

It’s the third vaccine to which Argentina gives its approval within only one week. The first was that of Pfizer that Antat entered in the Argentinian register of drugs, in the emergency framework of the pandemic.

It was December 23. Hours later, the Ministry of Health authorized the Russian vaccine. In this case, the Angat only emitted A recommendation for the government to be able to use it. Seven days later, the approval of the Oxford vaccine brought the year-end trilogy to a close.

PS